NTRK2 and glioma: The most remarkable aspect from a group of separate studies that were published at the same time is the comprehensive electrophysiological, imaging, and transcriptomic evidence confirming the broad expression of synaptic effectors, including TrkB (NTRK2), in a variety of glioma cells, and how those components can respond to the activity of surrounding neurons to promote the progression of both primary and secondary gliomas [310,311,312].